Stanley Druckenmiller at CNBC’s Delivering Alpha on Sept. 28, 2022.
Scott Mlyn | CNBC
A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox.
Investment firms of ultra-wealthy families are helping fuel the venture capital rebound in biotechnology. In August, family offices made 52 direct investments in private companies, with biotech startups representing about 20% of transactions, according to data provided exclusively to CNBC by Fintrx, a private wealth intelligence platform.
Stanley Druckenmiller’s Duquesne Family Office, one of the most active family offices in the U.S., has backed at least four pharmaceuticals or life sciences companies this year, according to Fintrx. Last month, Duquesne participated in a $90 million Series C round for Epicrispr Biotechnologies. The…
